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1. Introduction
Stem cells possess two main attributes, namely, a self-renewal capacity and multipotency. Self-
renewal refers to the ability of a cell to replicate itself without differentiating or losing
multipotency. Multipotency is the ability to differentiate into more than one cell lineage. Recent
studies have revealed that there are several types of stem cells. For example, neural stem cells
can differentiate into neurons, astrocytes, and oligodendrocytes, while hematopoietic stem
cells can differentiate into all types of blood cells. Embryonic stem (ES) cells were originally
established from the inner cell mass (ICM) of mouse blastocysts [1, 2]. As the ICM gives rise
to the embryo, ES cells can differentiate into most cell types in the body and are therefore
pluripotent. The successful establishment of human pluripotent cells, namely, human ES cells
and human induced pluripotent (iPS) cells, opens up the possibility of using these cells in
regenerative medicine [3-5]. However, several issues remain to be resolved. One such issue is
unanticipated tumor formation by transplanted pluripotent cells, which seems to be associated
with the self-renewal capacity of these cells.
The self-renewal of mouse ES cells [6, 7] can be maintained by the presence of leukemia
inhibitory factor (LIF) in the culture medium. LIF binds to LIF receptor (LIFR) and induces
formation of gp130/LIFR heterodimers, leading to activation of the downstream transcription
factor signal transducer and activator of transcription (STAT)-3. The LIF/STAT3 pathway plays
a critical role in ES cell self-renewal by upregulating several self-renewal genes [8]. The
expression of a set of self-renewal genes is also regulated by networks of important transcrip‐
tion factors, including Oct3/4, Sox2, and Nanog [9].
Cancer is one of the most feared diseases throughout the world. Approximately 10 million
people die from cancer every year and the number of cancer patients is increasing. This disease
is characterized by loss of cellular growth control, which is induced by genome alterations,
such as DNA sequence changes, copy number aberrations, chromosomal rearrangements, and
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modifications in DNA methylation. Recent studies have provided evidence that tumor tissue
contains a small subset of stem-like cells called cancer stem cells. Cancer stem cells have stem
cell-like attributes, namely, self-renewal and differentiation, which enables them to produce
tumors by self-renewing and giving rise to differentiated progeny. The concept of cancer stem
cells first arose from studies of leukemia stem cells [10] and subsequently of solid tumors [11,
12]. Given that cancer stem cells play a prominent role in cancer cell growth, it may be
reasonable to expect similarities between ES cells and cancer cells.
Indeed, ES cells are similar to cancer cells in several respects. When injected into immunode‐
ficient mice, ES cells and cancer cells can produce benign and malignant tumors, respectively.
Both cell types have a rapid cell cycle, which results in fast proliferation. Telomerase activity
is very high in both cell types, which allows them to proliferate indefinitely. Both cell types
contain a “side population of cells” with a high drug efflux capacity, which gives rise to their
drug-resistance phenotype. In addition, several signal transduction pathways seem to be used
in both ES cell self-renewal and cancer cell growth. For example, the STAT3 pathway, which
plays a central role in ES cell self-renewal, is activated in several types of cancer cells. On the
other hand, the Wnt/β-catenin pathway, whose activation is associated with tumorigenesis in
many tissues, is involved in ES cell self-renewal. Moreover, poorly differentiated tumors
preferentially overexpress genes that are normally enriched in ES cells [13].
The similarities between ES cells and cancer cells raise the possibility that certain molecules
that are involved in ES cell self-renewal play important roles in cancer cell growth, while
certain oncogenes play critical roles in ES cell self-renewal (Fig. 1). In this chapter, I will provide
examples of such molecules and describe their roles in ES cell self-renewal and tumorigenesis.
Figure 1. Similarity between ES cells and cancer cells.
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2. ES cell self-renewal genes that are involved in cancer cell growth
2.1. Oct3/4
Oct3/4 was originally isolated by three groups [14-16].  Since Oct1 and Oct2 had already
been identified, two groups named this protein Oct3, while the other group named it Oct4.
Therefore,  I  will  use the term “Oct3/4” to describe this protein.  Oct3/4 is a transcription
factor belonging to the POU family and is encoded by the pou5f1 gene. The Oct3/4 protein
contains three domains,  namely,  the N-terminal,  POU, and C-terminal  domains.  The N-
and C-terminal domains are transactivation domains with redundant functions, while the
POU domain is  a bipartite DNA-binding domain consisting of the POU-specific domain
and the POU homeodomain. In mouse development, deficiency of this transcription factor
results in loss of the ICM [17]. In agreement with this, conditional knockout of this gene
in ES cells results in their differentiation into trophectoderm cells [18], indicating that Oct3/4
is a central player in the self-renewal of ES cells. Furthermore, the recent finding that Oct3/4
is one of the four factors required for the production of iPS cells indicates the importance
of Oct3/4 for the acquisition of pluripotency [19].
Not only suppression, but also overexpression of Oct3/4 induces ES cell differentiation [18],
suggesting that the activity of Oct3/4 needs to be sustained at the correct level to main‐
tain ES cell self-renewal. Oct3/4 expression in ES cells is positively and negatively regulat‐
ed by multiple factors. The upstream region of the pou5f1 gene contains proximal and distal
enhancers, which regulate stem cell-specific expression of Oct3/4 [20]. An orphan nuclear
receptor Lrh1 (also known as Nr5a2) binds to the proximal enhancer to maintain Oct3/4
expression [21],  whereas Oct3/4 and Sox2 associate with the distal enhancer to stimulate
Oct3/4  expression [22].  Negative regulators  of  Oct3/4  expression include Gcnf,  Coup-tfs,
and  Cdx2,  whose  expression  are  induced  upon  ES  cell  differentiation.  In  addition  to
regulation of Oct3/4 expression, the transcriptional activity of Oct3/4 protein is regulated
by Oct3/4-binding proteins. For example, it  is well-established that Sox2 is a co-factor of
Oct3/4. β-catenin binds to Oct3/4 and functions as a co-activator that enhances the transcrip‐
tional activity of Oct3/4 [23]. The orphan nuclear receptor Dax1 also binds to Oct3/4, but
acts as a negative regulator by interfering with the binding of Oct3/4 to DNA [24].
In adult human tissues, expression of Oct3/4 is restricted to germline cells and is very low
in other tissues. By contrast, Oct3/4 is expressed in several types of human cancers, including
prostate,  breast,  oral,  bladder,  and  seminoma  [25],  suggesting  the  importance  of  this
transcription factor in cancer development. Moreover, Oct3/4 is highly expressed in cancer
stem-like cells in breast cancer, lung cancer, and bone sarcoma [26-28]. In lung cancer, Oct3/4
maintains the properties of cancer stem-like cells [28].  In agreement with these findings,
high expression of Oct3/4 significantly correlates with poor overall survival of nasopharyng‐
eal carcinoma patients [29].
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2.2. Sox2
Sox2 is a transcription factor that belongs to the SRY-related HMG-box protein (Sox) family.
The Sox2 protein contains one HMG box, as well as a transactivation domain in its C-terminus.
Expression of Sox2 in ES cells is mainly regulated by Oct3/4 and Sox2 itself. In addition,
microRNAs (miRNAs) are involved in the control of Sox2 expression. For example, miR-9
binds to the 3’-untranslated region of Sox2 mRNA and represses Sox2 expression [30]. In
addition to regulation at the transcriptional level, the activity of Sox2 protein is regulated by
post-translational modifications. Mouse Sox2 protein can be sumoylated at Lys-247, which
impairs its binding to the Fgf4 enhancer [31]. Additionally, acetylation of Lys-75 by p300/CBP
promotes the nuclear export of Sox2 [32]. Akt directly interacts with Sox2 to phosphorylate
Thr-118, leading to stabilization of the Sox2 protein [33].
Sox2-deficient mouse embryos die shortly after implantation [34], indicating that Sox2 is
required for early development. In ES cells, Sox2 usually cooperates with Oct3/4 to regulate
the expression of several self-renewal factors, including Nanog, and disruption of the sox2 gene
results in the differentiation of ES cells into trophectoderm-like cells [35]. In addition, Sox2
regulates expression of histone acetyltransferases, including Tip60 and Elp3, and forms a
positive feedback loop with the polycomb group protein Eed to control the levels of histone
acetylation and methylation [36]. Similar to Oct3/4, Sox2 is one of the four factors required for
iPS cell production [19].
Besides its pivotal role in maintaining ES cell self-renewal, Sox2 is closely associated with many
types of cancer [37]. The Sox2 gene is located at chromosome 3q26, a region that is frequently
amplified in carcinomas. Amplification of the Sox2 gene has been observed in human squa‐
mous cell carcinomas of the lung and esophagus [38]. Sox2 is involved in the tumorigenesis of
several types of tumors, such as lung, breast, skin, prostate, ovarian, and sinonasal. For
example, Sox2 is expressed in early-stage breast tumors, and high Sox2 expression is associated
with large tumor size [39, 40]. Sox2 expression in breast cancer enhances cancer stem cell-like
properties [40]. Sox2 is also reportedly involved in regulation of cancer stem-like cells in
ovarian carcinoma [41].
2.3. Nanog
Nanog was originally identified as a gene whose overexpression can bypass the LIF require‐
ment of mouse ES cells for self-renewal [42, 43]. Nanog protein can be ubiquitinated at its PEST
domain, resulting in its degradation through the proteasome pathway in ES cells [44].
Phosphorylation of Nanog prevents this ubiquitination, thereby increasing the stability of
Nanog [45].
Although Nanog-deficient ES cells expand at a slower rate than wild-type cells,  they can
self-renew and retain expression of Oct3/4 and Sox2 [46]. These observations suggest that
Nanog is involved in the growth of ES cells,  but is  dispensable for ES cell  self-renewal.
Human Nanog is a reprogramming factor that can produce human iPS cells [5]. In murine
cells, mouse Nanog accelerates reprogramming and promotes the transition of pre-iPS cells
into mature iPS cells [47].
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Normally, Nanog is expressed at early embryonic stages and in germline stem cells, but not
in adult tissues. However, Nanog is expressed at high levels in several types of cancers,
including breast, cervical, oral and kidney [48]. Nanog is also highly expressed in germ cell
tumors [49], which are characterized by the gain of the short arm of chromosome 12, at which
the Nanog gene is located. In addition, several reports have suggested that Nanog is involved
in the epithelial-mesenchymal transition and metastasis. For example, Nanog stimulates cell
migration and invasion in ovarian cancer through downregulation of E-cadherin and Foxj1 [50].
Nanog expression is higher in hepatocellular carcinoma cell lines that are highly metastatic
than in those that are lowly metastatic, and the Nodal/Smad3 pathway plays an important role
in the Nanog-stimulated epithelial-mesenchymal transition [51]. More importantly, Nanog
overexpression is associated with poor prognosis in some types of cancer, such as colorectal,
ovarian, and breast [48]
Nanog has 11 highly homologous pseudogenes in human cells. Of these, NanogP8 encodes a
full-length protein with only one amino acid difference from Nanog, and is involved in
tumorigenesis [52, 53]. It was recently shown that NanogP8 can function as a reprogramming
factor, with similar activity to Nanog [54].
2.4. STAT3
STAT3 is a downstream transcription factor of gp130, and is therefore activated by several
cytokines, including interleukin (IL)-6, IL-11, and LIF. This transcription factor was initially
identified as APRF (acute phase response factor), an inducible DNA-binding protein that binds
to the IL-6 response element within the promoters of genes that encode hepatic acute phase
proteins [55]. Human and mouse STAT3 proteins both have 770 amino acid residues and are
highly homologous to each other (only three amino acid differences). In addition to the DNA-
binding domain, STAT3 protein contains a SH2 domain, which facilitates dimer formation
upon phosphorylation by upstream kinases including JAK2. STAT3 protein is usually in an
inactive form and is localized in the cytoplasm. Upon cytokine stimulation, STAT3 is tyrosine-
phosphorylated by activated JAKs. Thereafter, the phosphorylated STAT3 protein forms a
homodimer or a heterodimer and translocates into the nucleus, where it stimulates the
transcription of its target genes. In mouse development, STAT3 activity is detected during
early post-implantation development [56] and Stat3-deficient mice die prior to gastrulation
[57], suggesting that STAT3 plays an important role in early embryogenesis.
STAT3 plays an indispensable role in the self-renewal of mouse ES cells, and deficiency of
STAT3 leads to the differentiation of these cells. By contrast, human ES cells do not require
STAT3 activation for their self-renewal. This discrepancy in the requirement for STAT3 is most
likely due to differences between mouse and human ES cells, as mouse ES cells are derived
from the ICM, whereas human ES cells are derived from the epiblast. Extensive studies have
identified many self-renewal factors that are downstream of STAT3 signaling, such as
transcription factors, epigenetic regulators, and oncogenes [8].
Although the STAT3 protein is normally only activated in response to signals that control cell
growth, overactivation of STAT3 protein has been observed in several types of cancer,
including breast, prostate, and pancreas, as well as leukemia and lymphoma [58]. Indeed,
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STAT3 is constitutively activated in nearly 70% of tumors. Because of the high frequency of its
overactivation, STAT3 is considered to be a valuable target for anti-cancer therapy.
2.5. Krüppel-like factor (Klf) 4
Klfs are a family of transcription factors that play important roles in many fundamental
biological processes. They were named “Krüppel-like” owing to their strong homology with
the Drosophila  gene product Krüppel,  which is involved in segmentation of the develop‐
ing embryo. Klf family proteins contain three C2H2-type zinc fingers that bind DNA. Klf4
was independently cloned by two groups and named “gut-enriched KLF” and “epithelial
zinc finger” owing to its high expression in the intestine and skin epithelium, respective‐
ly [59, 60]. However, it was later discovered that this transcription factor is expressed in
several other tissues, such as lung, testis, and thymus. In addition to a C-terminal DNA-
binding domain consisting of zinc fingers, Klf4 protein contains an activation domain in its
N-terminus and a repressive domain in its  central  region.  Probably owing to this  struc‐
ture, Klf4 is a bi-functional transcription factor that can either activate or repress transcrip‐
tion of its target genes. Similar to Oct3/4 and Sox2, Klf4 is one of the four factors that induce
reprogramming of murine cells [19].
Klf4 is highly expressed in self-renewing ES cells, but not in differentiated ES cells. Klf4
regulates self-renewal-specific expression of Lefty1, in cooperation with Oct3/4 and Sox2 [61].
Klf4 is also involved in Oct3/4 expression [62]. Overexpression of Klf4 results in the inhibition
of ES cell differentiation, possibly through upregulation of Nanog [63, 64]. In addition, there is
a marked overlap between genes that are regulated by Nanog and those that are regulated by
Klf4. These observations suggest the importance of Klf4 in ES cell self-renewal. However,
Klf4-null mice have no detectable defects during embryogenesis [65]. Furthermore, a recent
study reported that the function of Klf4 in ES cell self-renewal is partially redundant because
combined knockdown of Klf4, Klf2, and Klf5, but not any one gene individually, results in
spontaneous ES cell differentiation [62], suggesting that Klf4 is dispensable for ES cell self-
renewal.
In cancer cells, Klf4 acts as a tumor suppressor or an oncogene, possibly owing to its bi-
functionality. Whether Klf4 acts as a tumor suppressor or an oncogene likely depends on the
tumor type. For example, Klf4 functions as a tumor suppressor in the intestinal and gastric
epithelium, and expression of Klf4 is downregulated in human colorectal and gastric carcino‐
mas [66, 67]. On the other hand, overexpression of Klf4 in the skin results in squamous
epithelial dysplasia, eventually leading to squamous cell carcinoma [68, 69]. A high expression
level of Klf4 significantly correlates with a poor prognosis in hepatocellular carcinoma [70].
2.6. Zinc-finger protein (Zfp)-57
Zfp57 is a transcription factor that was originally identified as an undifferentiated cell-specific
gene in F9 embryonal carcinoma cells [71]. Mouse Zfp57 protein contains one Kruppel-
associated box (KRAB) domain and five zinc fingers, while human Zfp57 protein has one
KRAB domain and seven zinc fingers. In adult mouse, Zfp57 is highly expressed in testis and
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brain [71, 72]. Loss of the zygotic function of Zfp57 leads to partial lethality, while eliminating
both the maternal and zygotic functions of Zfp57 results in complete embryonic lethality [73].
Through its KRAB domain, Zfp57 interacts with KRAB-associated protein 1 (Kap1), a scaffold
protein for heterochromatin-inducing factors, and thus participates in genome imprinting by
recruiting Kap1 to multiple imprinting control regions [73, 74]. Mutations in the Zfp57 gene
cause transient neonatal diabetes mellitus type 1 [75]. Zfp57 is a downstream molecule of
STAT3 and Oct3/4 in ES cells, and is therefore specifically expressed in self-renewing ES cells
[76]. Zfp57 deficiency has no effect on the self-renewal or growth in ES cells, suggesting that
this transcription factor is dispensable for ES cell self-renewal.
Based on our prediction that a molecule expressed in self-renewing ES cells may play an
important role in cancer cell growth, we recently screened several ES cell-specific transcription
factors for their tumor-promoting activity, and found that Zfp57 can promote anchorage-
independent growth of human fibrosarcoma HT1080 cells [77]. Zfp57 overexpression enhan‐
ces, while its knockdown suppresses, HT1080 tumor formation in nude mice. Zfp57 regulates
the expression of insulin-like growth factor 2, which plays a critical role in Zfp57-induced
anchorage-independent growth and tumor formation. Furthermore, overexpression of Zfp57
causes anchorage-independent growth of the mouse immortal fibroblast cell line NIH3T3, and
immunohistochemical analysis revealed the overexpression of Zfp57 in several cancers,
including pancreatic, gastric, breast, colon, and esophageal. These results suggest that Zfp57
is an oncogene in some types of cancer. Moreover, we also found that Zfp57 is involved in
anchorage-independent growth of ES cells and that Zfp57-null ES cells form smaller teratomas
than the parental ES cells in immunodeficient mice, suggesting the importance of Zfp57 in
teratoma formation by ES cells.
3. Oncogenes that are involved in ES cell self-renewal
3.1. β-catenin
The importance of the Wnt pathway in tumorigenesis was recognized by identification of
adenomatous polyposis coli (APC) mutations in familial adenomatous polyposis [78, 79]. In
Wnt signaling, the Apc protein functions as a negative regulator and is involved in degradation
of β-catenin, the mammalian homologue of Drosophila Armadillo. β-catenin contains multiple
armadillo repeats in its central region and a transcriptional activator domain in its C-terminal
region. Human and mouse β-catenin proteins both have 781 amino acid residues and are
almost identical to each other (only one amino acid difference). β-catenin acts as a transcrip‐
tional co-activator and an adaptor protein for intracellular adhesion. In epithelial tissues, β-
catenin interacts with cadherins and α-catenin, and regulates epithelial cell growth and
intracellular adhesion. By contrast, in Wnt signaling, β-catenin is a major transcriptional
modulator and plays a crucial role in embryogenesis. In the absence of Wnt signaling, Apc
forms a complex with β-catenin and Axin. This leads to phosphorylation of β-catenin by
glycogen synthase kinase (GSK)-3β, which triggers degradation of β-catenin. When Wnt binds
to its receptor Frizzled, Disheveled is hyper-phosphorylated, which results in release of
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GSK3β from the β-catenin degradation complex and prevents phosphorylation of β-catenin
by GSK3β. Unphosphorylated β-catenin translocates into the nucleus, where it forms a
complex with Tcf/Lef and functions as a transcriptional co-activator.
In human cancers, such as colon cancer, the β-catenin/Tcf/Lef complex positively regulates the
expression of a variety of cancer-associated genes, including cyclin D, Tert, and c-Myc, to
promote tumorigenesis. Apc mutation leads to stabilization and accumulation of β-catenin in
nuclei. However, in some cancers, mutation of β-catenin itself renders this protein unable to
be phosphorylated, resulting in its stabilization.
Accumulated evidence suggests that Wnt/β-catenin signaling contributes to the maintenance
of ES cell self-renewal. For example, Apc-null ES cells show severe differentiation defects [80].
Undifferentiated ES cells can be maintained in a self-renewing state by using conditioned
medium from Wnt3a-expressing cells [81]. Furthermore, enforced expression of an activated
form of β-catenin maintains the self-renewal of ES cells, even in the absence of LIF [23, 82].
Expression of γ-catenin, which has a similar structure to β-catenin, partially sustains the self-
renewal of ES cells in the absence of LIF [23]. β-catenin binds to Oct3/4 to enhance its tran‐
scriptional activity in ES cells, leading to upregulation of Nanog, a target gene of Oct3/4 [23].
The Wnt/β-catenin pathway upregulates expression of STAT3, and this signaling converges
with that of LIF [83]. Similarly, Wnt and LIF work in synergy to maintain the pluripotency of
mouse ES cells [84]. On the other hand, the self-renewal of ES cells can be maintained without
β-catenin [85]. Taken together, these results suggest that β-catenin promotes, but is dispensa‐
ble, for ES cell self-renewal. Moreover, it was recently shown that ES cells lacking Wnt signaling
resemble epiblast stem cells in terms of their morphology and gene expression [86, 87]. This
suggests that Wnt/β-catenin signaling prevents the transition of ES cells from a naïve to a
primed pluripotent state. In addition, β-catenin regulates Tert expression in ES cells [88], as is
the case in cancer cells.
3.2. Gli
The zinc-finger transcription factor Gli is a central player in the Hedgehog (Hh)-mediated
signaling pathway, which plays a critical role during embryogenesis. Gli belongs to the Klf
family and has three isoforms in mammals, namely, Gli1, Gli2, and Gli3. Gli1 and Gli2 usually
act as transcription activators, while Gli3 is a transcription suppressor. All Gli proteins have
a DNA-binding domain consisting of C2-H2 class zinc fingers. In addition, Gli1 and Gli2
contain a C-terminal transactivation domain, while Gli2 and Gli3 have an N-terminal repres‐
sion domain. Hh family proteins, namely, Sonic Hh, Indian Hh, and Desert Hh, function as
ligands of the transmembrane receptor Ptch1. In the absence of a Hh ligand, Ptch1 inhibits the
activity of the G-protein coupled receptor-like protein Smo, resulting in formation of a complex
of Gli2 and Gli3 with the inhibitory protein Sufu. This results in cleavage of Gli2 and Gli3 into
their repressor forms, which translocate into the nucleus. By contrast, binding of Hh ligands
to Ptch1 results in the release and activation of Smo, leading to activation and nuclear trans‐
location of Gli2, which results in transactivation of target genes, including Gli1.
Gli1 was originally identified as an amplified gene in a human glioma cell line [89]. It was
recently shown that Hh/Gli signaling regulates the self-renewal of glioma stem cells, as well
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as their expression of stemness genes, including Oct3/4 and Sox2 [90]. Gli1 forms a positive
feedback loop with Nanog, and the Nanog/Gli1 signaling axis is indispensable for regulation
of glioma stem cells [91]. In Ewing sarcoma, expression of Gli1 is regulated in an Hh-inde‐
pendent manner: EWS-FLI, an oncogenic transcription factor that is produced by chromosomal
translocation, directly upregulates Gli1 expression to promote tumor growth [92, 93].
Gli1 and Gli2 are both highly expressed in undifferentiated ES cells, while Gli3 expression level
is low [94]. Gli1 and Gli2 are downstream molecules of Oct3/4 and Nanog, and their expression
is downregulated upon differentiation. When Gli1 and Gli2 are suppressed by a dominant-
negative mutant of Gli2, expression of the self-renewal marker Sox2 decreases, whereas that
of the differentiation markers Gata4 and Cdx2 increases, suggesting the importance of Gli
activity for ES cell self-renewal. However, expression of this dominant-negative Gli2 mutant
does not affect expression of the self-renewal markers Oct3/4 and Nanog. These findings
suggest that Gli activity is involved in repressing ES cell differentiation, but is dispensable for
ES cell self-renewal. In addition, Gli is involved in ES cell growth [94, 95].
3.3. Akt
The serine/threonine protein kinase Akt was independently identified by three different
groups. Two groups identified this kinase as being homologous to protein kinase C and protein
kinase A, giving rise to the names “protein kinase B” and “RAC-PK” (related to the A and C
kinases) [96, 97]. The other group identified this kinase as the cellular counterpart of the
oncogene v-akt of the acutely transforming retrovirus AKT8 that is found in a rodent T-cell
lymphoma [98]. Here, I will describe this protein as “Akt”. Akt has three isoforms, namely,
Akt1, Akt2, and Akt3. Each Akt family member has an N-terminal pleckstrin homology
domain, a short α-helical linker, and a C-terminal kinase domain. Akt is directly downstream
of phosphatidylinositol-3-OH kinase, and is a key player in the regulation of cell growth and
survival.
As expected from its identification as a counterpart of a viral oncogene, Akt plays an important
role in human malignancy [99, 100]. Several studies have identified amplification of the Akt
gene in human cancers. Amplification of Akt1 was detected in a human gastric cancer [101].
Amplification and overexpression of Akt2 were detected in ovarian and pancreatic cancers.
Artificial activation of Akt1 or Akt2 can transform NIH3T3 cells [102, 103], and Akt2 anti-sense
RNA inhibits the tumorigenic phenotype of pancreatic carcinoma cell lines [104]. Furthermore,
Akt1 kinase activity is often increased in prostate and breast cancers and is associated with a
poor prognosis [102].
A constitutively activated Akt mutant can maintain the undifferentiated phenotype of mouse
ES cells, even in the absence of LIF, although the mechanism underlying Akt-mediated
maintenance of ES cell self-renewal is unclear [105]. Bechard and Dalton demonstrated that
Akt phosphorylates, and thereby inactivates, GSK3β in ES cells, suggesting that Akt maintains
ES cell self-renewal by inactivating GSK3β and thus stimulating activation of β-catenin [106].
By contrast, Watanabe et al. did not observe the accumulation of β-catenin in nuclei or
activation of the transcriptional activity of β-catenin in mouse ES cells [105]. Another possible
Embryonic Stem Cells and Oncogenes
http://dx.doi.org/10.5772/57614
49
mechanism is that Akt induces expression of Tbx3, which in turn stimulates expression of
Nanog to maintain ES cell self-renewal [107].
3.4. c-Myc
c-Myc is a cellular counterpart of the v-myc gene, which was isolated from the avian retrovirus
MC29 [108], and belongs to a family of helix-loop-helix/leucine zipper transcription factors. c-
Myc forms a complex with Max, which results in the increased stability of c-Myc protein [109].
Phosphorylation of Thr-62 by Erk also stabilizes c-Myc, while phosphorylation of Thr-58 by
GSK3β reduces the stability of c-Myc [110]. c-Myc regulates expression of its target genes
through binding to E-box sequences and recruiting histone acetyltransferases. Under normal
conditions, when cells are stimulated by an internal or external growth-promoting signal, the
level of c-Myc rapidly and transiently increases to induce cell proliferation, and the level of c-
Myc subsequently returns to a low level in quiescent cells.
It is well-established that many, if not most, human tumors have elevated levels of c-Myc
owing to gene amplification and translocation [111, 112]. Gene amplification of c-Myc has been
reported in several cancers, including breast, ovarian, and colon. A common human translo‐
cation involving c-Myc is t(8;14), which is critical for the development of Burkitt's lymphoma.
Although c-Myc was one of the four factors originally identified as being required for iPS cell
production [19], generation of iPS cells without this transcription factor has been reported
[113], suggesting that c-Myc is dispensable for cell reprogramming.
During the self-renewal of ES cells, levels of c-Myc are elevated [114]. By contrast, upon LIF
withdrawal, the level of c-Myc mRNA decreases and c-Myc protein is phosphorylated on
Thr-58 by GSK3β, which triggers degradation of c-Myc. Expression of a stable c-Myc mutant,
in which the Thr-58 residue is mutated to alanine, allows ES cells to self-renew in the absence
of LIF. By contrast, expression of a dominant-negative form of c-Myc inhibits the self-renewal
of ES cells and induces their differentiation. These findings suggest that c-Myc is critically
involved in maintaining the self-renewal of ES cells. Moreover, analysis of Max-null ES cells
revealed that the function of c-Myc/Max in ES cell self-renewal seems to be largely independent
of the Oct3/4, Sox2, and Nanog regulatory networks [115].
4. Future prospective
As I have described here, several common transcription factors are involved in the regulation
of ES cell self-renewal and cancer cell growth (Fig. 2). This raises several intriguing possibilities.
Considering that these common transcription factors are stem cell-specific and are involved
in tumor growth, it is possible that they are specifically expressed in cancer stem cells and play
important roles in the growth of these cells. Therefore, it is possible that these factors are good
markers of cancer stem cells. If so, it might be possible to utilize these factors to isolate cancer
stem cells, which will help to advance cancer stem cell research. Furthermore, identification
of small compounds that specifically inhibit the functions of these factors may lead to the
development of new anti-cancer drugs that can selectively kill cancer stem cells.
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Since ES cells and iPS cells have similar gene expression profiles, it is likely that these common
transcription factors are also expressed in iPS cells. Considering the transforming potential of
these factors, it is possible that their high expression in iPS cells increases the risk of tumor
formation during cell therapy using iPS-derived cells. Indeed, we have already found that
Zfp57-null ES cells are significantly less able to form tumors than wild-type ES cells.
In this way, understanding the roles of putative oncogenes in ES cells will not only help to
elucidate the molecular basis underlying the similarity between ES cells and cancers cells, but
will also help to develop a novel method that can be used in cancer therapy and regenerative
medicine.
Figure 2. Transcription factor network that regulates ES cell self-renewal. Considering the similarities between ES cells
and cancer cells, at least a part of this network may be used for growth regulation in cancer cells.
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